GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Cyclically Adjusted Book per Share

CytoDyn (CytoDyn) Cyclically Adjusted Book per Share : $-0.04 (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CytoDyn's adjusted book value per share for the three months ended in Feb. 2024 was $-0.121. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-0.04 for the trailing ten years ended in Feb. 2024.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 20.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 22.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of CytoDyn was 34.10% per year. The lowest was 3.50% per year. And the median was 11.90% per year.

As of today (2024-06-01), CytoDyn's current stock price is $0.15776. CytoDyn's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2024 was $-0.04. CytoDyn's Cyclically Adjusted PB Ratio of today is .


CytoDyn Cyclically Adjusted Book per Share Historical Data

The historical data trend for CytoDyn's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Cyclically Adjusted Book per Share Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.06 -0.04 -0.02 -0.03

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.03 -0.04 -0.04

Competitive Comparison of CytoDyn's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, CytoDyn's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's Cyclically Adjusted PB Ratio falls into.



CytoDyn Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytoDyn's adjusted Book Value per Share data for the three months ended in Feb. 2024 was:

Adj_Book= Book Value per Share /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.121/130.9299*130.9299
=-0.121

Current CPI (Feb. 2024) = 130.9299.

CytoDyn Quarterly Data

Book Value per Share CPI Adj_Book
201405 0.066 100.373 0.086
201408 0.007 100.352 0.009
201411 -0.033 99.635 -0.043
201502 -0.067 99.032 -0.089
201505 -0.168 100.333 -0.219
201508 -0.084 100.548 -0.109
201511 -0.030 100.135 -0.039
201602 0.095 100.040 0.124
201605 0.083 101.355 0.107
201608 0.050 101.617 0.064
201611 0.039 101.829 0.050
201702 0.036 102.779 0.046
201705 -0.007 103.256 -0.009
201708 -0.055 103.587 -0.070
201711 -0.077 104.072 -0.097
201802 -0.036 105.052 -0.045
201805 -0.061 106.148 -0.075
201808 -0.085 106.383 -0.105
201811 -0.028 106.338 -0.034
201902 -0.021 106.649 -0.026
201905 -0.027 108.048 -0.033
201908 -0.018 108.245 -0.022
201911 -0.034 108.519 -0.041
202002 -0.009 109.139 -0.011
202005 -0.005 108.175 -0.006
202008 0.005 109.662 0.006
202011 -0.011 109.793 -0.013
202102 -0.026 110.968 -0.031
202105 -0.034 113.576 -0.039
202108 -0.039 115.421 -0.044
202111 -0.019 117.269 -0.021
202202 -0.031 119.703 -0.034
202205 -0.131 123.323 -0.139
202208 -0.116 124.958 -0.122
202211 -0.141 125.607 -0.147
202302 -0.128 126.928 -0.132
202305 -0.119 128.314 -0.121
202308 -0.126 129.538 -0.127
202311 -0.118 129.548 -0.119
202402 -0.121 130.930 -0.121

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


CytoDyn  (OTCPK:CYDY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CytoDyn Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of CytoDyn's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Industry
Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660

CytoDyn (CytoDyn) Headlines

From GuruFocus

CytoDyn Announces President Takes Medical Leave of Absence

By GlobeNewswire GlobeNewswire 05-24-2023

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

By GuruFocusNews GuruFocusNews 07-02-2022

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

By Value_Insider Value_Insider 11-22-2022